Treatment with BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) harboring NOTCH1 mutations was associated with significantly longer progression-free survival (PFS) compared with chemoimmunotherapy, according to findings from a…
Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL
